文献速递心脑血管急症重症综合管理与镇静镇痛

超级难治性癫痫持续状态的手术干预:一项系统综述

Surgical Interventions for Super-Refractory Status Epilepticus: A Systematic Review.
PubMed 文献 · Neurocrit Care · 2026-03-12
一句话结论系统综述显示,超级难治性癫痫持续状态患者接受急性神经外科干预后,111/114例SRSE终止,57/114例末次随访达Engel I级;作者认为可考虑手术干预,早期干预可能带来更好结局。

本文为一项按照PRISMA指南、PROSPERO注册方案实施的系统综述,检索至2024年2月的多个数据库,纳入儿童与成人超级难治性癫痫持续状态(SRSE)接受手术或神经调控干预的文献。共筛选1436条引文、审阅66篇稿件,识别114例接受急性神经外科干预的SRSE患者。主要结局为SRSE终止与末次随访Engel I级分类:111/114例术后SRSE终止,57/114例末次随访达Engel I级(无致残性发作)。亚组分析提示,即使病因为自身免疫性或遗传性,手术干预仍有效;SRSE起病后延迟超过3周手术者SRSE终止率与长期无发作率较低(40.7% vs 早期干预组70%),作者认为早期干预可能带来更好结局。

要点

  • 114例接受急性神经外科干预的SRSE患者中,111例术后SRSE终止,57/114例末次随访达Engel I级(无致残性发作)。
  • 剩余57例中,8例未存活,3例癫痫持续状态复发,46例仍有药物难治性癫痫,其中29例发作较前减少。
  • SRSE起病后延迟超过3周手术者SRSE终止率与长期无发作率较低(40.7% vs 早期干预组70%),作者认为早期干预可能带来更好结局。
  • 亚组分析提示,手术干预在自身免疫性与遗传性病因的SRSE患者中仍有效。
  • 作者结论认为,SRSE可考虑手术干预,即使病因为已知的遗传性或自身免疫性;早期干预可能带来更好结局。

适用人群与场景

  • 儿童与成人超级难治性癫痫持续状态(SRSE)患者,接受手术或神经调控干预。
  • SRSE定义为尽管常规使用麻醉药物管理仍持续超过24小时,或撤除麻醉后复发的癫痫持续状态。

诊断标准与关键阈值

  • SRSE定义:癫痫持续状态尽管常规使用麻醉药物管理仍持续超过24小时,或撤除麻醉后复发。

研究设计与关键结果

  • 研究类型:按照PRISMA指南、PROSPERO注册方案实施的系统综述,检索至2024年2月的多个数据库。
  • 共筛选1436条引文,审阅66篇稿件,识别114例接受急性神经外科干预的SRSE患者(儿童与成人)。
  • 主要结局:114例中111例术后SRSE终止;57/114例末次随访达Engel I级(无致残性发作)。
  • 剩余57例中:8例未存活,3例癫痫持续状态复发,46例仍有药物难治性癫痫,其中29例发作较前减少。
  • 亚组分析提示,手术干预在自身免疫性与遗传性病因的SRSE患者中仍有效。
  • SRSE起病后延迟超过3周手术者SRSE终止率与长期无发作率较低(40.7% vs 早期干预组70%)。

证据类型、等级与局限

  • 证据类型:系统综述(按照PRISMA指南、PROSPERO注册方案实施)。
  • 作者结论:手术干预可考虑用于SRSE治疗,即使病因为已知的遗传性或自身免疫性;早期干预可能带来更好结局。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,SRSE患者可考虑手术干预,即使病因为已知的遗传性或自身免疫性。
  • 作者认为,早期干预可能带来更好结局;SRSE起病后延迟超过3周手术者SRSE终止率与长期无发作率较低(40.7% vs 早期干预组70%)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Super-refractory status epilepticus (SRSE) is a neurological emergency defined as status epilepticus persisting for more than 24 h despite conventional management with anesthetics or recurrence with withdrawal of anesthesia. It is associated with high morbidity and mortality, and contemporary literature on treatment is limited. We present a systematic review of surgical interventions and outcomes for SRSE.

METHODS: We performed a multidatabase literature search according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, using an International Prospective Register of Systematic Reviews (PROSPERO)-registered protocol, to identify published literature through February 2024. Four reviewers independently screened citations, abstracts, and manuscripts of SRSE with surgical or neuromodulatory interventions in pediatric and adult populations, with a senior reviewer resolving discrepancies. The primary outcomes were the resolution of SRSE and Engel I classification at the last reported follow-up.

RESULTS: We screened 1436 citations, reviewed 66 manuscripts, and identified 114 patients who underwent acute neurosurgical intervention for SRSE. Of the 114 cases, 111 had resolution of SRSE after the intervention, and 57 of 114 patients were reported to be Engel class I (free of disabling seizures) at the last follow-up. Among the remaining half (57), 8 patients did not survive, 3 had recurrence of status epilepticus, and 46 continued to have medically refractory seizures, with 29 experiencing fewer seizures than before. Our subgroup analyses also highlighted that surgical interventions were effective even in patients with underlying autoimmune and genetic etiologies. An additional striking finding was that the patients who had surgical interventions delayed beyond 3 weeks from the SRSE onset were less likely to achieve resolution of SRSE and had poorer longitudinal seizure freedom (40.7%), in contrast to earlier intervention groups (70%), favoring early intervention.

CONCLUSIONS: Our work demonstrates that surgical interventions may be considered for the treatment of SRSE, even in cases with a known genetic and autoimmune etiology, and earlier intervention may lead to better outcomes.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Barnagian D, In E, Xiong Y, et al. Surgical Interventions for Super-Refractory Status Epilepticus: A Systematic Review. Neurocrit Care. 2026. PMID: 41817835. doi:10.1007/s12028-026-02448-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。